Seeking Alpha

Salix Pharmaceuticals (SLXP +7.1%) spikes higher on volume 3X normal trading activity after...

Salix Pharmaceuticals (SLXP +7.1%) spikes higher on volume 3X normal trading activity after Auriga upgrades it to a Buy rating with a $54 price target. Analysts call the firm's 2012 guidance conservative and indicate that they see a high likelihood that Salix will outperform.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)